Clinical Trials
57 trialsNCT07431281 2026-05-27
Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
AstraZeneca
Phase 3 Recruiting
NCT06469944 2026-05-26
MK-3475-06C
Merck Sharp & Dohme LLC
Phase 1/2 Recruiting
NCT05152147 2026-05-19
HERIZON-GEA-01
Jazz Pharmaceuticals
Phase 3 Active not recruiting
NCT04379596 2026-05-13
DG-03
AstraZeneca
Phase 2 Recruiting
NCT07177794 2026-04-21
EC-CRT-008
Sun Yat-sen University
Phase 3 Recruiting
NCT03161522 2026-04-15
Chemotherapy With or Without Radiation or Surgery in Treating Participants With Oligometastatic Esophageal or Gastric Cancer
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT03764553 2026-04-07
LyRICX
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Phase 2 Active not recruiting
NCT04430738 2026-02-24
Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers
Seagen Inc.
Phase 2 Active not recruiting
NCT06123338 2026-01-29
A Study of Pembrolizumab With Trastuzumab and Chemotherapy in People With Esophagogastric Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT06065371 2025-12-19
Sacituzumab Govitecan in Combination With Capecitabine for Advanced Gastrointestinal Cancers After Progression on Standard Therapy
Henry Ford Health System
Phase 1 Recruiting
NCT07233850 2025-11-18
A Phase II Clinical Study Evaluating SSGJ-706 in Combination Therapy for Advanced Gastrointestinal Cancers
Shenyang Sunshine Pharmaceutical Co., LTD.
Phase 2 Not yet recruiting
NCT01191697 2025-11-03
CAPOX, Bevacizumab and Trastuzumab for Patients With HER2-Positive Metastatic Esophagogastric Cancer
Dana-Farber Cancer Institute
Phase 2 Completed
NCT03929666 2025-09-12
A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer
Jazz Pharmaceuticals
Phase 2 Completed
NCT05007106 2025-08-14
KEYVIBE-005
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT00680901 2025-08-07
LOGiC - Lapatinib Optimization Study in ErbB2 (HER2) Positive Gastric Cancer: A Phase III Global, Blinded Study Designed to Evaluate Clinical Endpoints and Safety of Chemotherapy Plus Lapatinib
Novartis
Phase 3 Completed
NCT03153280 2025-07-08
Lithium
Cancer Trials Ireland
Phase 1 Terminated
NCT01404156 2024-08-28
POWERRANGER
CancerCare Manitoba
Phase 2/3 Completed
NCT03641547 2024-07-18
CHARIOT
University of Oxford
Phase 1 Completed
NCT02735239 2024-03-22
Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Oesophageal Cancer
Ludwig Institute for Cancer Research
Phase 1/2 Completed
NCT02954536 2023-03-16
Phase II Trial of Pembrolizumab With Trastuzumab and Chemotherapy in Advanced HER2 Positive Esophagogastric (EG) Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT01726452 2022-09-30
NEOadjuvant Trial in Adenocarcinoma of the oEsophagus and oesophagoGastric Junction International Study (Neo-AEGIS)
Cancer Trials Ireland
Phase 3 Completed
NCT04390945 2022-02-03
Camrelizumab Combined With CRT for Treatment of Patients With Local Recurrence of Esophageal Cancer
The First Affiliated Hospital of Henan University of Science and Technology
Phase 2 Unknown
NCT00193128 2021-11-24
Preoperative Therapy With Oxaliplatin/Docetaxel/Capecitabine and Radiation in Resectable Esophagus Cancer
SCRI Development Innovations, LLC
Phase 1/2 Completed
NCT02128243 2021-03-26
MATEO
AIO-Studien-gGmbH
Phase 2 Completed
NCT00183898 2019-05-16
Study of Oxaliplatin and Xeloda and Cetuximab as First Line Treatment for Metastatic or Unresectable Gastric or Gastroesophageal Junction Cancer
University of Southern California
Phase 2 Unknown
NCT01490749 2019-03-15
Trial of XELOX Followed by Radiation Combined With Carboplatin and RAD001 for Esophageal Cancer
Emory University
Phase 1 Completed
NCT02177552 2019-02-15
SEED
Rigshospitalet, Denmark
Phase 2 Unknown
NCT01386346 2018-12-12
VEOX
Weill Medical College of Cornell University
Phase 1 Completed
NCT00215644 2018-11-02
MATRIX EG
Merck KGaA, Darmstadt, Germany
Phase 2 Completed
NCT02741856 2018-10-25
SCOPE2
Velindre NHS Trust
Phase 2/3 Unknown
NCT00003867 2018-09-10
Irinotecan and Capecitabine in Treating Patients With Solid Tumors
Montefiore Medical Center
Phase 1 Completed
NCT02358863 2018-09-06
mEGA
Georgetown University
Phase NA Terminated
NCT02216149 2018-08-28
FluoHeart
Helsinki University Central Hospital
Phase 2 Terminated
NCT00891878 2018-07-24
Capecitabine With or Without Sunitinib Malate as First-Line Therapy in Treating Patients With Metastatic Cancer of the Esophagus or Gastroesophageal Junction
Alliance for Clinical Trials in Oncology
Phase 2 Completed
NCT00938470 2018-03-29
Docetaxel, Oxaliplatin, Capecitabine, Fluorouracil, and Radiation Therapy in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction
Alliance for Clinical Trials in Oncology
Phase 2 Completed
NCT00848783 2018-01-08
Irinotecan/Cisplatin, Potentially Curative Surgery With or Without Floxuridine, Followed by Capecitabine for Stomach and Gastro-esophageal Junction (GEJ) Cancers
NYU Langone Health
Phase 2 Terminated
NCT00054457 2016-12-13
Docetaxel and Capecitabine in Treating Patients With Metastatic Cancer of the Stomach or Gastroesophageal Junction
Alliance for Clinical Trials in Oncology
Phase 2 Completed
NCT00040859 2016-12-07
Oxaliplatin and Capecitabine in Treating Patients With Advanced Esophageal Cancer or Stomach Cancer
Alliance for Clinical Trials in Oncology
Phase 2 Completed
NCT00130936 2016-02-15
Study of Epirubicin (Pharmorubicin®), Carboplatin (Paraplatin®) and Capecitabine (Xeloda®) (ECC) in the Treatment of Unresectable Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Cancer With Pharmacogenetic Correlates
AHS Cancer Control Alberta
Phase 1/2 Terminated
NCT00737438 2016-02-03
Pre-operative Chemotherapy Plus Bevacizumab With Early Salvage Therapy Based on PET Assessment of Response in Patients With Locally Advanced But Resectable Gastric and GEJ Adenocarcinoma
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00578071 2015-07-02
POXX
Duke University
Phase 1/2 Completed
NCT00447330 2015-02-13
XAGastric
Duke University
Phase 2 Completed
NCT00153881 2014-11-13
Docetaxel and Carboplatin Followed by Oral Capecitabine, Docetaxel and Radiation for Esophageal Cancer
Dartmouth-Hitchcock Medical Center
Phase 1 Completed
NCT01843829 2014-03-24
NeoSCOPE
Velindre NHS Trust
Phase 2 Unknown
NCT00719550 2013-12-05
AMG 102 Plus ECX for Unresectable Locally Advanced or Metastatic Gastric or Esophagogastric Junction Cancer
Amgen
Phase 1/2 Completed
NCT00470184 2013-11-25
Oxaliplatin, Capecitabine, and Radiation Therapy in Patients Undergoing Surgery for Stage II, III, IV Esophageal Cancer
Roswell Park Cancer Institute
Phase 2 Completed
NCT00909402 2013-06-21
A Study of BMS-833923 With Cisplatin and Capecitabine in Inoperable, Metastatic Gastric, Gastroesophageal, or Esophageal Adenocarcinomas
Bristol-Myers Squibb
Phase 1 Completed
NCT00238147 2013-05-17
Combination Chemotherapy and Radiation Therapy in Treating Patients Who Are Undergoing Surgery for Locally Advanced Esophageal Cancer
University of Washington
Phase 1 Completed
NCT00281788 2013-03-21
Combination Chemotherapy and Radiation Therapy in Treating Patients With Esophageal Cancer or Gastroesophageal Junction Cancer
Duke University
Phase 1 Completed
NCT00509561 2012-12-18
Cisplatin, Capecitabine, and Radiation Therapy With or Without Cetuximab in Treating Patients With Esophageal Cancer
Wales Cancer Trials Unit
Phase 2/3 Unknown